



RECEIVED

08 MAY 28 AM 6:03

DuPont Haskell Global Centers
for Health and Environmental Sciences
1090 Elkton Road, P.O. Box 50
Newark, DE 19714-0050

May 23, 2008

Via Federal Express

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency, ICC Building
1201 Constitution Ave., NW
Washington, DC 20004



Dear 8(e) Coordinator:

8EHQ-06-16391
Copper Hydroxide

This letter is to inform you of the results of a recently conducted acute oral toxicity study in rats with a proprietary R&D mixture containing 23 % of the above referenced substance.

A single dose of test mixture was administered by oral gavage to 1 fasted female rat at a dose of 175 mg/kg, to 2 fasted female rats at a dose of 550 mg/kg, to 4 fasted female rats at a dose of 1750 mg/kg, and to 3 fasted female rats at a dose of 5000 mg/kg. The rats were dosed one at a time at a minimum of 48-hour intervals. The rats were observed for mortality, body weight effects, and clinical signs for up to 14 days after dosing. All rats were necropsied to detect grossly observable evidence of organ or tissue damage.

Death occurred in 3 of the 4 rats dosed at 1750 mg/kg and in 2 of the 3 rats dosed at 5000 mg/kg. The estimated oral LD₅₀ in female rats is 1681 mg/kg.

The surviving rat dosed at 550 mg/kg exhibited lethargy on the day of dosing and high posture up to the day after dosing. One rat dosed at 1750 mg/kg exhibited lethargy and high posture 2-4 days after dosing and was found dead 5 days after dosing. Another rat dosed at 1750 mg/kg exhibited lethargy and was found dead on the day of dosing. Hyperreactivity was observed on the day of dosing and 2 days after dosing in the surviving rat dosed at 5000 mg/kg.

This information is submitted in accordance with current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act or, where it is not clear that reporting criteria have been met, it is submitted as a precautionary measure and because it is information in which EPA may have an interest.

Sincerely,

A. Michael Kaplan, Ph.D.
Director - Regulatory Affairs and Occupational Health

AMK/MB: clp
(302) 366-5260

Contains No CBI

CONTAINS NO CBI



311895